Heaptitis B virus (HBV) is a noncytopathic, hepatotropic virus belonging to the hepadnaviridae family. Infection of HBV can be either transient or chronic in nature (13, 30) .
Transient infection frequently leads to acute hepatitis and, in rare cases, results in fatal, fulminant hepatitis (30) . Chronic infection represents a major public health burden affecting an estimated 400 million individuals worldwide and carries a high risk for the development of chronic active hepatitis, cirrhosis and primary hepatocellular carcinoma (43) . As for many other viruses, the outcomes of HBV infections and pathogenesis of the associated diseases are determined by virus-host interactions, largely mediated by innate and adaptive immune responses (8, 73) .
Virus infection elicits a rapid and potent innate immune response in mammalian cells to produce pro-inflammatory cytokines and chemokines that limit virus replication and coordinate adaptive antiviral immunity (50) . Central to this cellular response is the virus-induced production of alpha/beta interferons (IFN-α/β), which play an indispensible role in host defense against virus infections (22, 45, 61) . In the last decade, tremendous progresses have been made in uncovering the cellular pattern recognition receptors (PRRs) that sense diverse pathogenassociated molecular patterns (PAMPs) and deciphering the molecular pathways that couple pathogen recognition to the induction of IFNs and other cytokines (50, 66, 71) . Notably, mammalian cells sense virus infections predominantly via either endosomal Toll-like receptors 3, 7/8 and 9 (TLR3, TLR7/8, and TLR9) or cytoplasmic caspase activation and recruitment domain (CARD)-containing DEx(D/H) box RNA helicases, including retinoic acid-inducible gene I (RIG-I) and melanoma differentiation associated gene 5 (MDA5) (1, 79) . While the four TLRs are activated by selective binding of viral double stranded RNA (TLR3), single-stranded poly-U RNA (TLR7/8) or unmethylated CpG DNA motifs present in viral genomes (TLR9) in the endosomes (2, 24, 39) , RIG-I and MDA5 recognize cytoplasmic viral RNAs bearing
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distinguishable structural features from cellular RNA, such as the presence of triphosphates at the 5' terminus (31, 51) . As illustrated in Fig. 1 , recognition of such virus-associated molecular patterns by each of the cellular PRRs recruits their distinct adaptor proteins which activate signaling cascades to induce cytokine production in virally infected cells. For examples, binding of viral RNA to RIG-I/MDA5 induces conformation changes that lead to the exposure of their CARD domains (65) . Through homotypic CARD interaction with the interferon promoter stimulator 1 (IPS-1, also known as CARDIF, MAVS and VISA) adaptor protein, the RIG-I/MDA5 is recruited onto the outer membrane of the mitochondria to form a macromolecular signaling complex that serves to activate downstream interferon regulatory factor 3 (IRF3), nuclear factor κ B (NFκB), c-Jun/ATF2 and other transcription factors that stimulate the transcription of IFNs and certain IFN-stimulated genes (ISGs) (38, 44, 59, 77) . Similarly, engagement of the TLRs with viral nucleic acids recruits distinct adaptor proteins TRIF (for TLR3) or MyD88 (for TLR7/8 and TLR9), which initiates signaling pathways to activate critical transcription factors, such as NFκB, IRF3, IRF7 or IRF5 among others, to induce expression of pro-inflammatory cytokines and other cellular genes (37) .
Microarray analyses of host cellular gene expression profiles in response to infections of the variety of viruses in cultured cells and tissue samples obtained from infected people and animals in the last decade reveal that induction of ISG expression, a indicator of the activation of PRR-mediated host cellular antiviral responses, is observed in almost all the virus infections examined, with rare exceptions (34, 72) . One of such exceptions is HBV infection of chimpanzees (73) . While it had been shown that induction of ISGs in the livers of chimpanzees and humans was a hallmark of hepatitis C virus (HCV) infections (5, 6, 27, 40, 60, 62) , HBV infection of chimpanzees did not induce the expression of ISGs as the virus spreads throughout
the liver (73) . This surprising and unprecedented observation implies that HBV either fails activate or has evolved ability to inhibit the activation of the PRR-mediated innate immune responses.
To resolve these issues and determine whether activation of PRR-mediated innate immunity in human hepatoma cells could inhibit HBV replication, we investigated the induction and antiviral effects of TLRs-and RIG-I/MDA5-mediated host cellular innate immune responses against HBV in HepG2 and Huh7 cells via overexpression of the three PRR adaptors, IPS-1, TRIF and MyD88. Our results demonstrated that expressing each of the three adaptors potently inhibited HBV replication, predominantly through intracellular antiviral pathway(s), rather than secreted cytokines. Most strikingly, we found that unlike IFN-α/β inhibition of HBV replication in mouse hepatocytes, where the cytokines prevented pregenomic (pg) RNA-containing nucleocapsid formation (74) , the innate immune response-elicited by expression of adaptor proteins in human hepatoma cells limited HBV replication by reducing the steady-state levels of viral mRNAs. Analysis of involved signaling pathways revealed that activation of NFκB is essential for all three adaptors to elicit antiviral response in both HepG2 and Huh7 cells, but activation of IRF3 is only essential for induction of antiviral response by IPS-1 in Huh7 cells, but not HepG2 cells. Our results thus suggest that although HBV fails to activate host cellular innate defense pathways, it is extremely sensitive to the antiviral effects elicited by PRR-mediated host cellular antiviral response in human hepatocyte-derived cells. Further analysis of the intracellular antiviral pathway could potentially lead to the identification of molecular targets for the development of antivirals that evoke the intricate cellular antiviral pathway(s) and eliminate HBV infections.

MATERIALS AND METHODS
Cell culture and kinase inhibitors. HepG2 cells were obtained from ATCC and maintained in DMEM/F12 medium (Invitrogen) supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 µg/ml streptomycin. Huh7 cells were maintained as previously described (20) . MAPK inhibitors SB202190, U0126 and SP600125 were purchased from Calbiochem.
Plasmid construction. Plasmids pHBV1.3 and pCMV-HBV were described previously (19) . Plasmid pS that expresses HBV small (S) envelope proteins (HBsAg) was described previously and kindly provided by Volker Bruss (University of Gottingen, Germany) (55) . Plasmid pcHBs-V5, which expressed C-terminally V5 tagged HBsAg, was generated by insertion of a 0.8bk PCR fragment spanning the HBsAg coding region into pcDNA3.1/V5-His-TOPO vector. Plasmids expressing C-terminally HA-tagged MyD88, TRIF with deletion of carboxyl terminal 68 amino acids (saTRIF), and constitutively active (or superactive) interferon regulatory factor 3 (saIRF3) proteins were purchased from Invivogen (San Diego, California). Plasmids expressing wild-type IκB-alpha (IκBα) and dominant negative IκB-alpha (DN-IκBα) were obtained from Christoph Seeger (Fox Chase Cancer Center, Philadelphia). Plasmids expressing other adaptors or cellular signaling proteins used in this study were constructed via similar approaches described previously (35) . Briefly, to obtain cDNA clones of human RIG-I, MDA5, CARD domains of RIG-1 and MDA5, IPS-1 and IRF3, first strand cDNA was made from Huh7 cell-derived total RNA with oligo-(dT) [12] [13] [14] [15] [16] [17] [18] primer and Superscript III DNA polymerase (Invitrogen) by following the manufacturer's direction. Full-
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length cDNA for each of the fore-mentioned genes with N-terminal FLAG tag was amplified by PCR (primer sequences are available upon request). The purified PCR fragments were digested with restriction enzymes Alf II and Not I and cloned into pcDNA5/FRT/∆CAT vector that was derived from pCDNA5/FRT/CAT (Invitrogen) by removing CAT-coding sequence with Apa I and Xho I digestion and self-ligation (35) . The plasmid expressing the dominant-negative IRF3 (DN-IRF3) was generated by amplification of the coding region for the amino acid 55 to 452 of IRF3 (42) and cloned into pcDNA5/FRT/∆CAT as described above. The identity of each cDNA clone was verified by nucleotide sequence analysis. NFκ κ κ κB DNA binding activity assay. Cell nuclear extracts were obtained by using Nuclear Extract kit (Active Motif), the protein concentration was determined by BCA assay (Pierce). Two and half micrograms of nuclear extract were subjected to NFκB p65 DNA binding ELISA assay (Active Motif) according to the manufacturer's protocol. Interestingly, because HBV pgRNA and 2.1kb mRNA ( Fig. 3B and C) , but not the 1.0kb
RESULTS
Activation of the host cellular innate immune response inhibits HBV replication in
truncated HBsAg mRNA (Fig. 3D) , are efficiently reduced in HepG2 cells that over-express the PRR adaptors, it is reasonable to conclude that RNA sequence element(s) located in the 3' overlapping region of the three HBV mRNA species may be critical for the selective reduction of viral RNAs. (Fig. 5, lanes 2 and 3) . However, it is surprising that the viral RNA levels were not affected or reduced less than 20% in HepG2 and Huh7 cells treated with conditioned medium harvested from the cells transfected with plasmid expressing TRIF, MyD88 or saIRF3 (Fig. 5, lanes 6 to 8) . with IPS-1-expressing plasmid, which reduced the level of viral RNA by 80% (Fig. 2B, lane 3 and Fig. 2C ).
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Hence, these results suggest that the observed strong inhibition of HBV replication by the three PRR adaptors is predominantly mediated by inducible intracellular factor(s), rather than secreted cytokines. It will be interesting to determine the intracellular signaling pathways that mediated the antiviral responses elicited by the PRR adaptors, which will ultimately lead to the identification of cellular factors that decrease the levels of HBV RNAs. Fig. 8A and B, comparing lanes 6, 9 and 12). Third, although ISG56 mRNA was induced by IPS-1 and TRIF in both HepG2 and Huh7 cells, and as expected, the induction was inhibited by expression of DN-IRF3, the levels of HBV mRNAs were only restored by DN-IRF3 in Huh7, but not HepG2 cells that overexpressed IPS-1( Fig. 8A and B, comparing lanes 4 and 7) . On the contrary, cotransfection of plasmid expressing DN-IκBα efficiently attenuated the antiviral effects of IPS-1 in both HepG2
and Huh7 cells (Fig. 8A and B, comparing lanes 4 and 10) . Finally, TRIF induced antiviral response can only be partially attenuated by expression of DN-IκBα in the two cell lines, but
expression of DN-IRF3 had no effect ( Fig. 8A and B 
DISCUSSION
Our work presented in this report shows that either IFN treatment or over-expression of the adaptors that mediate the signaling of the major viral PRRs non-cytopathically inhibited HBV replication in human hepatocyte-derived cell lines (Fig. 2) . Moreover, three lines of evidence support the notion that the PRR adaptor-elicited antiviral response was mediated by intracellular factors, rather than secreted cytokines. First, the adaptor-induced antiviral response was far more potent than that induced by high concentrations of IFN-α or IFN-λ ( Fig. 2 and Fig.   5 ). Second, treatment of HBV genome-transfected HepG2 and Huh7 cells with culture medium harvested from the adaptor-expressing plasmid-transfected HepG2 and Huh7, respectively, did not significantly inhibit HBV replication (Fig. 5) . Finally, analyses of the involved signal transduction pathways in the adaptor-induced antiviral response suggested that activation of IRF3 is only essential for induction of antiviral response by IPS-1 in Huh7 cells, but not essential for all three adaptors to induce antiviral response in HepG2 cells (Fig. 8) . It is well-known that IRF3 is essential for the induction of type I and type III IFNs by both IPS-I and TRIF. Hence, IFNs should not be the mediators of adaptor-induced antiviral response in HepG2 cells (Fig. 8 ).
In addition, it is worth noting that the primary effect of either IFNs or host cellular innate immunity elicited by the PRR adaptors on HBV replication in HepG2 and Huh7 cells is to reduce the steady-state levels of viral RNAs, but not to inhibit viral DNA replication (Figs. 2 and 3 ).
Previous studies with HBV transgenic mice or duck hepatitis B virus (DHBV) infected primary duck hepatocytes indicated that there are several distinct intracellular mechanisms that can be activated by innate and/or adaptive immune responses to limit hepadnavirus replication. 
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Hence, it is possible that the molecular mechanism by which the innate immunity controls HBV replication is species-specific. In our effort to determine if the observed reduction of HBV RNAs upon overexpression of the three adaptors is via the transcriptional and/or post-transcriptional mechanisms, we found that both HBV pgRNA and 2.1kb subgenomic RNA can be efficiently reduced by the three adaptors in a HBV promoter-independent manner. However, the level of a 1.0kb truncated HBV mRNA that spans only the coding region of HBV small envelope protein (HBsAg) was not affected by the three adaptors in HepG2 cells (Fig. 3) . These results suggest that the reduction of 
